Clinical Trial

Dapagliflozin for Long COVID Syndrome

Name: Dapagliflozin for Long COVID Syndrome — clinical trial record (NCT06907251)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DALCO

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2025-03-31; most recent amendment 2026-06-30.

Trial Details

NCT Number	NCT06907251
Lead Sponsor	Ottawa Heart Institute Research Corporation
Conditions	COVID - 19, Long COVID Syndrome, SARS CoV-2
Enrollment	192 participants
Start Date	2026-09-01
Primary Completion	2028-06-30 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-01